COMMUNIQUÉS West-GlobeNewswire

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
24/04/2025
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO [...]
Communiqué de presse : Sanofi : forte performance au T1 et confirmation des perspectives pour 2025
24/04/2025
Sanofi : forte performance au T1 et confirmation des perspectives pour 2025 Paris, le 24 avril 2025 Ventes du T1 en progression de 9,7 % à TCC 1 et BNPA 2 des activités de 1,79 euro Les ventes des nouveaux lancements [...]
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
24/04/2025
Allschwil, Switzerland, April 24, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
24/04/2025
Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPREME-2 trial [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter
24/04/2025
Group sales grew by 6% 1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions. Pharmaceuticals Division sales rose by 8% (9% in CHF) on continued strong demand [...]
Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
24/04/2025
Geneva, Switzerland, April 24, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological [...]
Merus annonce l’acceptation de son résumé pour présentation au congrès annuel 2025 de l’ASCO®
24/04/2025
- Le pétosemtamab en association avec le pembrolizumab en traitement de première intention d'un CETC r/m PD-L1+ : premières données cliniques provisoires sélectionnées pour une présentation sous forme d’affiche - [...]
Test Your Poison Launches Drug Testing Kits to Improve Public Safety and Address Drug Contamination Risks at Festivals and Nightclubs
24/04/2025
New drug testing kits help festival goers detect dangerous substances, promoting safer choices and harm reduction Test Your Poison Logo LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Test Your Poison, a leader in harm [...]
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
24/04/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of [...]
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
24/04/2025
ROCKVILLE, Md. and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to [...]
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
23/04/2025
– Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression – – Detailed [...]
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
23/04/2025
ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]
Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2024 Financial Results
23/04/2025
CARLSBAD, California, April 23, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal [...]
Aptose Announces Auditor Not Standing for Re-Appointment
23/04/2025
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug [...]
Jushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025
23/04/2025
BOCA RATON, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF) , a vertically integrated, multi-state cannabis operator, announced that it expects to [...]
Amedisys Reports First Quarter 2025 Financial Results
23/04/2025
BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 [...]
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
23/04/2025
WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
23/04/2025
Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement Estimates of annual incidence of LMs with cutaneous [...]
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
23/04/2025
SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]

Pages